Exploring olfactory receptor family 7 subfamily C member 1 as a novel oral cancer stem cell target for immunotherapy.
OR7C1
cancer immunotherapy
cancer stem cell
oral cancer
peptide vaccine
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
revised:
10
05
2023
received:
19
01
2023
accepted:
14
05
2023
medline:
5
9
2023
pubmed:
22
6
2023
entrez:
22
6
2023
Statut:
ppublish
Résumé
The mortality rate of oral cancer has not improved over the past three decades despite remarkable advances in cancer therapies. Oral cancers contain a subpopulation of cancer stem cells (CSCs) that share characteristics associated with normal stem cells, including self-renewal and multi-differentiation potential. CSCs are tumorigenic, play a critical role in cancer infiltration, recurrence, and distant metastasis, and significantly contribute to drug resistance to current therapeutic strategies, including immunotherapy. Cytotoxic CD8+ T lymphocytes (CTLs) are key immune cells that effectively recognize peptide antigens presented by the major histocompatibility complex class I molecules. Increasing evidence suggests that cancer antigen-specific targeting by CTLs effectively regulates CSCs that drive cancer progression. In this study, we utilized data from public domains and performed various bioassays on human oral squamous cell carcinoma clinical samples and cell lines, including HSC-2 and HSC-3, to investigate the potential role of olfactory receptor family 7 subfamily C member 1 (OR7C1), a seven transmembrane G-protein-coupled olfactory receptor that is also expressed in nonolfactory tissues and was previously reported as a novel marker and target of colon cancer initiating cell-targeted immunotherapy, in CSC-targeted treatment against oral cancer. We found that the OR7C1 gene was expressed only in oral CSCs, and that CTLs reacted with human leukocyte antigen-A24-restricted OR7C1 oral CSC-specific peptides. Taken together, our findings suggest that OR7C1 represents a novel target for potent CSC-targeted immunotherapy in oral cancer.
Identifiants
pubmed: 37344992
doi: 10.1111/cas.15873
pmc: PMC10475777
doi:
Substances chimiques
Receptors, Odorant
0
Peptides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3496-3508Subventions
Organisme : Japan Society for the Promotion of Science
ID : 19K10292
Organisme : Japan Society for the Promotion of Science
ID : 19K10337
Organisme : Japan Society for the Promotion of Science
ID : 20K18702
Informations de copyright
© 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Oral Oncol. 2015 Jul;51(7):704-8
pubmed: 25936651
Cancer Res. 2013 May 15;73(10):3051-61
pubmed: 23542356
Nature. 2007 Jan 4;445(7123):111-5
pubmed: 17122771
Stem Cell Res Ther. 2013;4(6):156
pubmed: 24423398
Oral Oncol. 2009 Jul;45(7):633-9
pubmed: 19027347
Nature. 2021 Sep;597(7875):279-284
pubmed: 34471285
Clin Cancer Res. 2016 Jul 1;22(13):3298-309
pubmed: 26861454
Nature. 2012 Jan 18;481(7381):306-13
pubmed: 22258609
Int J Cancer. 1998 Aug 12;77(4):538-42
pubmed: 9679755
Nature. 2006 Dec 7;444(7120):756-60
pubmed: 17051156
Cancer Sci. 2014 Apr;105(4):389-95
pubmed: 24450541
PLoS One. 2017 Mar 1;12(3):e0171460
pubmed: 28248963
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Stem Cells Transl Med. 2014 Mar;3(3):356-64
pubmed: 24375541
Cancer Res. 2012 Jun 1;72(11):2844-54
pubmed: 22552285
J Natl Cancer Inst. 2008 May 7;100(9):672-9
pubmed: 18445819
Cancer Cell. 2009 Aug 4;16(2):137-48
pubmed: 19647224
Cell. 2005 Sep 23;122(6):947-56
pubmed: 16153702
Oncotarget. 2016 Mar 8;7(10):11223-37
pubmed: 26849232
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8
pubmed: 12629218
Cancer Res. 2009 Nov 1;69(21):8241-8
pubmed: 19843861
Cancer Res. 2003 Sep 15;63(18):5821-8
pubmed: 14522905
Biochem Biophys Res Commun. 2005 Jul 22;333(1):264-72
pubmed: 15950192
Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8
pubmed: 17210912
Nat Med. 2011 Mar;17(3):313-9
pubmed: 21386835
Dev Biol. 1996 Apr 10;175(1):1-13
pubmed: 8608856
Cancer Res. 2009 Dec 1;69(23):8886-93
pubmed: 19903840
Biochem Biophys Res Commun. 2013 Sep 13;439(1):96-102
pubmed: 23954638
Clin Cancer Res. 2011 Oct 1;17(19):6174-84
pubmed: 21856769
Nat Rev Cancer. 2008 Oct;8(10):755-68
pubmed: 18784658
Cancer Immunol Res. 2018 Mar;6(3):358-369
pubmed: 29371260
J Immunother. 2009 Jun;32(5):474-85
pubmed: 19609239
Nat Rev Cancer. 2013 Oct;13(10):727-38
pubmed: 24060864
J Pathol. 2011 Mar;223(4):470-81
pubmed: 21294121
BMB Rep. 2012 Nov;45(11):612-22
pubmed: 23186999
Cell Stem Cell. 2007 Sep 13;1(3):313-23
pubmed: 18371365
Clin Cancer Res. 2006 Oct 1;12(19):5615-21
pubmed: 17020963
J Clin Oncol. 2016 Feb 10;34(5):427-35
pubmed: 26644536
Nature. 1994 Feb 17;367(6464):645-8
pubmed: 7509044
Cancer Sci. 2016 Jan;107(1):12-7
pubmed: 26440127
Nature. 2009 Apr 9;458(7239):780-3
pubmed: 19194462
Cancer Sci. 2015 Oct;106(10):1377-84
pubmed: 26202045
Cancer Lett. 2013 Jan 1;328(1):144-51
pubmed: 22935675
Mol Ther. 2009 Feb;17(2):219-30
pubmed: 19066601
Cancer Sci. 2023 Sep;114(9):3496-3508
pubmed: 37344992
Am J Pathol. 2011 Apr;178(4):1805-13
pubmed: 21435460
Genes Dev. 2003 May 15;17(10):1253-70
pubmed: 12756227
Cancer Res. 2007 Feb 1;67(3):1030-7
pubmed: 17283135
J Neurochem. 1999 Jun;72(6):2301-11
pubmed: 10349839
Annu Rev Cell Dev Biol. 2007;23:675-99
pubmed: 17645413
Mol Med Rep. 2015 May;11(5):3642-6
pubmed: 25544110
N Engl J Med. 2006 Feb 9;354(6):567-78
pubmed: 16467544